



December 8, 2016

## **Genocea to Host Virtual R&D Day on December 14th, 2016**

CAMBRIDGE, Mass., Dec. 08, 2016 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, will host a virtual Research and Development (R&D) Day for analysts, investors and media on Wednesday, December 14, 2016, starting at 8:30 a.m. ET. This event will be available via webcast and conference call only.

During the virtual R&D Day, members of the Genocea leadership team and leading physicians will provide a comprehensive overview of lead product candidate GEN-003 for the treatment of genital herpes, which is expected to enter Phase 3 development in 2017, and share how the Company is applying its unique and proprietary T cell antigen identification platform, ATLAS™, to immuno-oncology and cancer vaccine development.

### **Webcast & Conference Call Information**

A live webcast of the R&D Day can be accessed by visiting the "Events and Presentations" tab of the investor relations section of the Genocea website at <http://ir.genocea.com>. A replay of the webcast will be archived for 30 days following the presentation.

Interested participants and investors may also join the event by conference call by dialing (800) 708-4540 (domestic) or (847) 619-6397 (international) and referencing the conference ID 43927983.

### **About Genocea Biosciences Inc.**

Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. T cells are increasingly recognized as a critical element of protective immune responses to a wide range of diseases, but traditional discovery methods have proven unable to identify the targets of such protective immunity. Using ATLAS™, its proprietary technology platform, Genocea identifies these targets to potentially enable the rapid development of medicines to address critical patient needs. Genocea's pipeline includes GEN-003, a novel T cell-enabled immunotherapy for genital herpes in Phase 2 clinical development, and earlier-stage investments in immuno-oncology. For more information, please visit the company's website at [www.genocea.com](http://www.genocea.com).

For media:

Liz Bryan

Spectrum Science Communications, Inc.

O: 202-955-6222

[lbryan@spectrumscience.com](mailto:lbryan@spectrumscience.com)

For investors:

Jonathan Poole

Genocea Biosciences, Inc.

O: 617-876-8191

[jonathan.poole@genocea.com](mailto:jonathan.poole@genocea.com)

 Primary Logo

Source: Genocea Biosciences

News Provided by Acquire Media